The Supreme Court ruled in FTC vs. Actavis, that courts are required to apply a rule of reason analysis in determining whether a reverse payment settlement violates antitrust laws. The reverse payment settlement, which is unique to pharmaceutical litigation, enables a patent-holder to maintain exclusivity in the relevant market and keep prices higher than they would or should be.